SLC5A2 and heart failure: Interestingly, data supporting a positive impact of SGLT2 inhibitors on the E/e ́ ratio are more consistent for individuals at risk of developing heart failure (i.e., heart failure at American Heart Association (AHA) stage A/B) [13–15] as compared with individuals with symptomatic heart failure of AHA stage C [16–18].